Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects

Executive Summary

Sponsor's proposal for a label warning, but not a black box, on retinopathy risk with the once-weekly GLP-1 agonist finds support from a US FDA advisory committee, which overwhelming endorsed approval for treatment of type 2 diabetes on the basis of robust glycemic control efficacy data and a strong cardiovascular safety profile.

You may also be interested in...



Keeping Track: Approvals, A Burst Of Submissions, And Some Priority Reviews

The latest drug development news and highlights from our US FDA Performance Tracker.

Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic

Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).

EU CHMP To Decide On New Drugs For Asthma, Diabetes, Hemophilia A, Ovarian Cancer – And Roche’s Ocrevus

Products for a wide range of diseases are expecting a CHMP opinion this week, including orphan drugs for ovarian cancer, eosinophilic esophagitis, and CMV infection, and therapies for asthma, diabetes, and hemophilia A. Roche will be hoping its multiple sclerosis drug Ocrevus can finally clear the CHMP hurdle.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel